Statins May Help Reduce Severe COVID-19 Outcomes
Author Information
Author(s): Eric A. Meyerowitz, Arthur Y. Kim
Primary Institution: Montefiore Medical Center
Hypothesis
Does baseline statin use reduce the risk of severe COVID-19 outcomes?
Conclusion
Baseline statin use appears to reduce the likelihood of severe COVID-19 outcomes, especially before widespread vaccination.
Supporting Evidence
- Statin use was associated with a reduction in serious COVID-19 outcomes.
- 84% of participants in both groups received COVID-19 vaccines by the end of the study.
- The risk of serious COVID-19 was lower in the pitavastatin group compared to the placebo group.
Takeaway
Taking statins before getting COVID-19 might help you not get very sick from it, especially before vaccines were available.
Methodology
The study analyzed data from the REPRIEVE trial to examine the relationship between baseline statin use and COVID-19 outcomes.
Potential Biases
Potential confounding factors related to statin use may affect the results.
Limitations
The study did not meet the prespecified threshold for statistical significance due to a low number of severe events.
Participant Demographics
Participants were individuals with HIV, with 95% on treatment for over a year.
Statistical Information
P-Value
< .0001
Confidence Interval
95% CI, 0.52–1.03
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website